Patients with Hodgkin's disease (HD) that is either refractory to standard chemotherapy or relapses after autologous stem cell transplant (SCT) have very poor long-term outcome. Results of allogeneic SCT from HLAmatched siblings in this group of patients have shown that, although transplant-related mortality is high, 1,2 long-term disease-free survival is still possible, supporting the concept of a graft-versus-HD effect. Unfortunately, many of these patients do not have HLA-matched siblings.
Umbilical cord blood (UCB) is now considered an acceptable source of stem cells for adult patients needing allogeneic SCT but without an HLA-matched sibling. The application of UCB transplant to adult patients with hematologic malignancies has rapidly expanded in the last few years, especially after the report of the successful use of hematopoietic stem cells (HSC) pooled from two different units of unrelated UCB that may not necessarily be HLAmatched. 3 UCB transplant is particularly suited for patients needing 'urgent' transplants for refractory disease. Unlike unrelated HSC transplants, in which there is usually a delay in the availability of the HSC for transplant due to the search process and procurement of the HSC, UCB procurement is fast and can usually be accomplished in 2-3 weeks. In addition, the stringent matching criteria needed for unrelated HSC transplants are not as important in UCB transplants. The incidence of graft-versus-host disease (GVHD) is also lower. 4, 5 However, the majority of UCB transplants have been carried out for acute leukemias. Literature on the application of UCB transplant for relapsed/refractory HD is scarce. To date, there has only been one report specifically describing the use of UCB transplant in nine patients with relapsed/refractory HD. 6 All nine patients received a non-myeloablative conditioning regimen and the 2-year progression-free survival was 25%. In two other published papers on the use of UCB transplant for hematologic malignancies that included HD, 4, 7 only two patients with HD were included in each study and the outcomes of these patients were not specifically reported. Therefore, if the impact and clinical applicability of UCB transplant in the treatment of patients with relapsed/refractory HD is to be determined, more cases are needed in the database. Here, we report the successful use of a single unit two antigen-mismatched UCB in the salvage of a patient with HD that relapsed promptly following an autologous SCT.
A 23-year-old female was diagnosed with low risk Stage IIA nodular sclerosing HD in December 2002. She received combination chemotherapy with standard adriamycin, bleomycin, vincristine and decarbazine (ABVD). She achieved a PET-CT scan documented first complete remission (CR1) after four cycles and treatment was stopped after six cycles of chemotherapy. However, her disease relapsed three months after completing the last cycle of chemotherapy. PET-CT scan on this occasion showed jugular, axillary and mediastinal metabolically active lymphadenopathy. She proceeded to two cycles of dexamethasone, high-dose ARA-C and cisplatinum combination chemotherapy (DHAP), achieving a PET-CT documented CR2 after the first cycle. Autologous HSC were harvested, followed by a consolidative autologous SCT with high-dose carmustine, etoposide, ARA-C and melphalan (BEAM), with the intention to proceed to mantle radiation therapy on day þ 100 after transplant. However, her disease relapsed in her left para-aortic nodes inferior to the aortic arch and upper paratracheal nodes on day þ 64. Mantle radiation was commenced immediately. She had a repeat PET-CT scan after completion of the radiation therapy and on this occasion, the scan showed she had further disease progression outside the area of radiation, involving the head of pancreas and the right hepatic lobe. She received further local radiation to these sites. A repeat PET-CT scan after the local radiation showed further disease progression, involving the lymph nodes above and below the diaphragm. Based on the obvious poor prognosis of this patient, an allogeneic SCT was recommended to exploit a graft-versus-HD effect. As she did not have any HLA-matched siblings, it was decided to salvage the patient with high-dose chemotherapy followed by an unrelated UCB transplant. The patient received two cycles of mustine, vincristine, procarbazine and prednisone while waiting for the insurance approval and procurement of the UCB.
She weighed 64 kg and her full HLA types were as follows: HLA-A2, 29; B15, 35; DRB1*0802, 1103. She received oral busulfan (16 mg/kg) and intravenous highdose cyclophosphamide (120 mg/kg) with mesna cover, followed by the infusion of a 4/6 HLA-matched unit of previously cryopreserved unrelated UCB 10 months after her autologous SCT. The full HLA types of the infused cord blood were: HLA-A2, A26, B15, 35; DRB1*0404, 1103. Therefore, there was a mismatch at each of the HLA-A and DRB1 locus. A total of 2.23 Â 10 7 /kg nucleated cells and 2.05 Â 10 5 /kg CD34 þ cells were infused. GVHD prophylaxis consisted of cyclosporine A starting day À2.
She engrafted, achieving an absolute neutrophil count of 40.5 Â 10 9 /l on day þ 18 and became platelet transfusion independent on day þ 67. The transplant was complicated by Grade III skin GVHD, metabolic seizure disorder and self-limiting hemorrhagic cystitis. GVHD was promptly controlled with methylprednisone and this was discontinued by day þ 56. Cyclosporine A was withdrawn on day þ 100. As on 1 March 2008, the patient has remained well without any immunosuppressive agents and in CR3 without significant chronic GVHD, 41 þ months after her UCB transplant. She is back to full time employment and has a Karnofsky score of 100.
This case demonstrates that some patients with refractory/relapsed HD can be salvaged with UCB transplant with resulting long-term disease-free survival. UCB should, therefore, be considered for these patients if they fail autologous SCT and do not have any HLA-matched siblings for allogeneic SCT. More HD patients are, however, needed in the database to identify those who will benefit most from this treatment approach. 
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